Alterity Therapeutics Gets $3.9M R&D Tax Refund
Ticker: PRNAF · Form: 6-K · Filed: Mar 26, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $3.9 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: tax-refund, r&d, financing
TL;DR
Alterity just got a $3.9M R&D tax refund, boosting their cash for drug development.
AI Summary
Alterity Therapeutics Ltd. announced on March 26, 2024, that it received a $3.9 million R&D Tax Incentive Refund. This refund is a significant boost to the company's financial resources, supporting its ongoing development efforts.
Why It Matters
This substantial cash inflow provides Alterity Therapeutics with increased financial flexibility to fund its research and development activities, potentially accelerating its drug development pipeline.
Risk Assessment
Risk Level: low — The filing is a routine report of a tax refund, which is generally positive news with low inherent risk.
Key Numbers
- $3.9M — R&D Tax Incentive Refund (Provides significant financial support for the company's development activities.)
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant and recipient of the R&D tax incentive
- $3.9 million (dollar_amount) — Amount of the R&D Tax Incentive Refund received
- March 2024 (date) — Period for which the Form 6-K is filed
- 20240326 (date) — Filing date of the report
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report that Alterity Therapeutics Limited received a $3.9 million R&D Tax Incentive Refund.
When was the R&D Tax Incentive Refund received by Alterity Therapeutics?
The filing is for the month of March 2024, and the refund is reported as received by Alterity Therapeutics.
What is the amount of the R&D Tax Incentive Refund?
The R&D Tax Incentive Refund received by Alterity Therapeutics is $3.9 million.
How is this filing being incorporated into other SEC filings?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 and Form F-3.
What was Alterity Therapeutics' former company name?
Alterity Therapeutics' former company name was PRANA BIOTECHNOLOGY LTD.
Filing Stats: 194 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-03-26 08:00:02
Key Financial Figures
- $3.9 million — submitted: 99.1 Alterity Receives a $3.9 million R&D Tax Incentive Refund 1 SIGNATURE
Filing Documents
- ea0202565-6k_alterity.htm (6-K) — 14KB
- ea020256501ex99-1_alterity.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-025771.txt ( ) — 29KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Receives a $3.9 million R&D Tax Incentive Refund 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: March 26 , 2024 2